Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 5;13(1):6.
doi: 10.3390/antib13010006.

Clinical and Analytical Performance of ELISA Salivary Serologic Assay to Detect SARS-CoV-2 IgG in Children and Adults

Affiliations

Clinical and Analytical Performance of ELISA Salivary Serologic Assay to Detect SARS-CoV-2 IgG in Children and Adults

Andrea Padoan et al. Antibodies (Basel). .

Abstract

Saliva is a promising matrix with several purposes. Our aim is to verify if salivary anti-SARS-CoV-2 antibody determination is suitable for monitoring immune responses. One hundred eighty-seven subjects were enrolled at University-Hospital Padova: 105 females (56.1%) and 82 males (43.9%), 95 (50.8%) children and 92 (49.2%) adults. Subjects self-collected saliva using Salivette; nineteen subjects collected three different samples within the day. A serum sample was obtained for all individuals. The N/S anti-SARS-CoV-2 salivary IgG (sal-IgG) and serum anti-SARS-CoV-2 S-RBD IgG (ser-IgG) were used for determining anti-SARS-CoV-2 antibodies. The mean (min-max) age was 9.0 (1-18) for children and 42.5 (20-61) for adults. Of 187 samples, 63 were negative for sal-IgG (33.7%), while 7 were negative for ser-IgG (3.7%). Spearman's correlation was 0.56 (p < 0.001). Sal-IgG and ser-IgG levels were correlated with age but not with gender, comorbidities, prolonged therapy, previous SARS-CoV-2 infection, or time from last COVID-19 infection/vaccination. The repeatability ranged from 23.8% (7.4 kAU/L) to 4.0% (3.77 kAU/L). The linearity of the assay was missed in 4/6 samples. No significant intrasubject differences were observed in sal-IgG across samples collected at different time points. Sal-IgG has good agreement with ser-IgG. Noninvasive saliva collection represents an alternative method for antibody measurement, especially in children.

Keywords: ELISA; SARS-CoV-2 antibodies; adults; children; salivary samples.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Linearity assessment for six samples. Linearity was assessed by polynomial regression. Dots are the concentration obtained from dilution. The blue color line is the dilution expected and the red color line is the dilution obtained.
Figure 2
Figure 2
Intrasubject differences in anti-SARS-CoV-2 N/S IgG across all collected samples. The circle dots represent the concentration of in anti-SARS-CoV-2 N/S IgG in the early morning while the square and triangular points the concentrations in the late morning and early afternoon respectively.

Similar articles

Cited by

References

    1. Statement on the Fourteenth Meeting of the International Health Regulations (2005) Emergency Committee regarding the Coronavirus Disease (COVID-19) Pandemic. World Health Organization (WHO); Geneva, Switzerland: 2023.
    1. Craig K.J.T., Rizvi R., Willis V.C., Kassler W.J., Jackson G.P. Effectiveness of Contact Tracing for Viral Disease Mitigation and Suppression: Evidence-Based Review. JMIR Public Health Surveill. 2021;7:e32468. doi: 10.2196/32468. - DOI - PMC - PubMed
    1. Cosma C., Galla L., Padoan A., Furlan G., Marchioro L., Zaninotto M., Basso D., Plebani M. SARS-CoV-2 specific T-cell humoral response assessment after COVID-19 vaccination using a rapid direct real-time PCR amplification. Clin. Chem. Lab. Med. (CCLM) 2023;61:1652–1660. doi: 10.1515/cclm-2023-0129. - DOI - PubMed
    1. Padoan A., Cosma C., Bonfante F., Della Rocca F., Barbaro F., Santarossa C., DallOlmo L., Pagliari M., Bortolami A., Cattelan A., et al. SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2 BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assays. Clin. Chim. Acta. 2021;523:446–453. doi: 10.1016/j.cca.2021.10.028. - DOI - PMC - PubMed
    1. Sheikh-Mohamed S., Sanders E.C., Gommerman J.L., Tal M.C. Guardians of the oral and nasopharyngeal galaxy: IgA and protection against SARS-CoV-2 infection. Immunol. Rev. 2022;309:75–85. doi: 10.1111/imr.13118. - DOI - PMC - PubMed

LinkOut - more resources